Blood Transfusion - 3 2016 (May - June)
Efficacy of autologous platelet-rich plasma for the treatment of muscle rupture with haematoma: a multicentre, randomised, double-blind, placebo-controlled clinical trial
Authors:  Ma José Martinez-Zapata, Lluís Orozco, Ramon Balius, Robert Soler, Alba Bosch, Gil Rodas, Lluís Til, Xavier Peirau, Gerard Urrútia, Ignasi Gich, Xavier Bonfill on behalf of the PRP-RICE group
Pages:  245-54
To cite this article:  Blood Transfus 2016; 14: 245-54
Doi:  10.2450/2015.0099-15
Published online:  21/09/2015

Background. The goals of the treatment of muscle injuries are to shorten the time of healing and to avoid relapses. The aim of this study was to assess the efficacy of autologous platelet-rich plasma (PRP) in the healing of muscle injuries.
Materials and methods. A multicentre, randomised, double-blind, parallel, controlled clinical trial was conducted in 71 patients (81.8% males) aged 45.6 (SD=10.0) years with muscle tears in the legs and haematoma. The haematoma was evacuated in all patients. Thirty-three patients were randomised to a single dose of autologous PRP and 38 patients to simulation of PRP administration. The primary end-point was time to complete recovery of muscle injury. Secondary end-points were pain, relapses, ultrasound parameters, and adverse events. The total follow-up per patient was 12 months.
Results. Time to complete recovery after the treatment was 31.63 days (SD=15.38) in the PRP group, and 38.43 days (SD=18.58) in the control group (p=0.261). Pain decreased over time in both groups without statistical differences between them. Eight patients relapsed (seven in the control group, and one in the PRP group). There were no adverse effects related to the interventions.
Discussion. Autologous PRP did not significantly improve the time to healing compared to that in the control group.

Keywords: muscle injuries, haematoma, tennis leg, platelet-rich plasma, growth factors.
Full Text Download Supplementary Content Back
Share this article: